GSE203547
An herbal medicine-based formula affected the epithelial cell line, BEAS-2B, genes expression.
Coronavirus Disease 2019 (COVID-19) remains a threat on the fatal ARDS with an incidence rate of 41.8%, or irreversible pulmonary fibrosis, without specific effective therapeutic drugs. The infection causes dysregulation of the immune system with a cytokine storm in lung tissue. To define the drug candidate of Virofree to COVID-19 induced-ARDS, we treated 66.67 ug/ml and 500 ug/ml in epithelial cell line, BEAS-2B, and compared the PBS control group to obtain Virofree expression profiles. Overall design: Examination of 2 different concentrations of Virofree in BEAS-2B cells.